Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Efficacy and Safety of TMC207 in Subjects With Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)

NCT01600963 is registered in ClinicalTrials.gov with Janssen Infectious Diseases BVBA as lead sponsor.

NCT NCT01600963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01600963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Efficacy and Safety of TMC207 in Subjects With Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)
Lead sponsor
Janssen Infectious Diseases BVBA
Phase
Phase 3
Overall status
Withdrawn
Start date
March 31, 2014
Completion date
November 30, 2022
Enrollment
0 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

multi-drug resistant tuberculosis